Early access without RWE is a missed commercial opportunity

Early Access Programmes are still too often treated as a necessary but temporary bridge, a way to supply patients with serious or life-threatening disease while regulatory and reimbursement processes catch up. In Europe, these programmes take many forms, from compassionate use and named-patient supply to formal cohort or national early-access schemes. What unites them is urgency: patients who cannot wait, clinicians who are prepared to act, and sponsors operating in a space of heightened scrutiny.

What is less consistently recognised is that Early Access also represents the first true encounter between a medicine and real clinical practice. This encounter produces evidence. The question is whether that evidence is allowed to emerge haphazardly, or whether it is intentionally shaped into something that can inform future decisions. Increasingly, the difference between those two approaches determines whether Early Access remains a short-term obligation or becomes a long-term strategic advantage.

Clinical trials are designed to answer specific questions under controlled conditions. Populations are tightly defined, protocols are rigid, and outcomes are selected to maximise internal validity. Early Access sits at the opposite end of that spectrum. Patients are more heterogeneous, disease is often more advanced, and clinicians prescribe based on judgement rather than protocol. Adherence reflects real life rather than trial compliance, and treatment pathways evolve dynamically. Precisely because of this lack of control, Early Access provides insight that trials cannot. It reveals how a medicine is actually used, where it truly fits in the pathway, and which patients derive the most meaningful benefit outside the artificial boundaries of development programmes.

For many rare disease, oncology, advanced therapy and highly specialised products, Early Access may represent the largest pre-commercial exposure the product ever has in Europe. In those cases, the data generated during this period can shape perceptions long before formal launch. Choosing not to think seriously about real-world evidence in Early Access is therefore not a neutral decision; it is a choice to allow the evidence narrative to form by default.

A persistent myth in this space is that any data collected during Early Access is inherently valuable. In reality, regulators and payers are selective. They assess not just what was collected, but why and how. Data that appears to influence prescribing behaviour, resembles an interventional study, or blurs the boundary between access and promotion quickly becomes problematic. Authorities across Europe are consistent in expecting non-interventional intent, clear separation from commercial activity, appropriate ethical oversight, and proportionality. Early Access is not meant to be a covert Phase IV programme. When those principles are respected, however, regulators are increasingly open to real-world evidence from Early Access as contextual and supportive material, particularly in small populations where randomised data will always be constrained.

The real divide, then, is not between programmes that collect data and those that do not, but between evidence that is accidental and evidence that is designed. Accidental evidence emerges when countries operate independently, each collecting whatever information seems locally convenient. Variables differ, data quality is uneven, and there is no clear hypothesis about how the information will be used later. Such datasets rarely survive serious regulatory, payer, or HTA scrutiny. At best, they generate internal anecdotes; at worst, they expose inconsistencies that undermine future value claims.

Designed real-world evidence looks very different. It starts with a small number of forward-looking questions: what uncertainties will regulators raise at approval, what assumptions will payers challenge at reimbursement, and what aspects of real-world use will matter most for long-term adoption. From those questions flows a deliberately limited dataset, applied consistently across markets and collected in a way that fits naturally into routine clinical care. The ambition is not exhaustiveness, but relevance. Early Access becomes the opening chapter of an evidence story that continues through launch and beyond.

Importantly, the most valuable evidence generated in Early Access is rarely headline efficacy. Trials already address that question. The real strategic value lies in understanding treatment positioning, patient selection, system impact, and treatment experience. Early Access shows where a medicine is actually used in practice, how clinicians sequence it relative to other options, and why they switch or persist. It highlights which sub-populations benefit most and which derive limited value, often revealing patterns that were invisible in controlled development settings. It also sheds light on resource utilisation, such as hospitalisations avoided or care pathways simplified, information that is often central to payer decision-making but difficult to demonstrate convincingly in trials. Finally, it captures the lived reality of treatment burden and tolerability, factors that strongly influence uptake once a product moves into routine use.

Europe’s fragmented Early Access landscape complicates this picture but also enriches it. Differences in eligibility thresholds, funding mechanisms, and clinical autonomy create natural variation. When viewed in isolation, this fragmentation feels inefficient. When connected through a common evidence framework, it becomes an analytical strength. Patterns that hold across divergent systems tend to be robust, while differences between countries highlight where assumptions may not generalise. Sponsors that allow each country to operate as a silo lose this perspective; those that harmonise evidence capture across markets effectively turn Europe into a distributed learning system.

The influence of Early Access real-world evidence on pricing and reimbursement is often indirect but significant. Such data rarely dictates list price, but it strongly affects the credibility of the value narrative. Evidence that supports unmet need beyond trial populations, validates budget impact assumptions, or demonstrates real-world system benefits can materially de-risk payer discussions. Conversely, poorly governed data that exposes high discontinuation rates or unexpected utilisation patterns can undermine confidence. Once again, the key issue is not whether data exists, but who controls its interpretation.

Operationally, the challenge is to embed evidence generation without undermining access itself. Early Access exists to serve patients first. Successful programmes therefore favour minimal datasets, light-touch digital capture, and clear governance boundaries. The aim is not to burden clinicians or delay treatment, but to capture decision-relevant insight as a by-product of care rather than an additional obligation. When done well, this approach respects the ethical foundations of Early Access while still delivering meaningful strategic value.

The most advanced organisations have moved beyond debating whether to collect real-world evidence in Early Access. Instead, they ask which future decisions would be materially improved by having real-world data, and which risks would be mitigated by earlier insight. In that framing, Early Access becomes a bridge between development and commercialisation, a proving ground for value hypotheses, and a source of optionality rather than exposure. The evidence generated does not replace trials, HTA submissions, or post-marketing studies; it connects them into a coherent lifecycle.

Early Access will always begin with patients, and it must remain grounded in that purpose. But in an environment of compressed launches, intense payer scrutiny, and growing reliance on real-world validation, it no longer makes sense for Early Access to end with anecdotes. When real-world evidence is treated as a strategic asset rather than an operational afterthought, Early Access becomes more than a stopgap. It becomes one of the most powerful tools available to shape how a medicine is understood, valued, and ultimately adopted in European healthcare systems.